Sidoti Estimates Prenetics Global’s Q3 Earnings (NASDAQ:PRE)

Prenetics Global Limited (NASDAQ:PRE) – Research analysts at Sidoti cut their Q3 2027 earnings per share (EPS) estimates for shares of Prenetics Global in a research report issued on Friday, February 20th. Sidoti analyst A. Hantman now forecasts that the company will post earnings of $0.71 per share for the quarter, down from their previous forecast of $0.76. The consensus estimate for Prenetics Global’s current full-year earnings is ($3.30) per share. Sidoti also issued estimates for Prenetics Global’s Q4 2027 earnings at $1.19 EPS and FY2027 earnings at $1.65 EPS.

PRE has been the topic of several other research reports. Cantor Fitzgerald lifted their price target on Prenetics Global from $26.00 to $32.00 and gave the company an “overweight” rating in a research note on Wednesday, October 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Prenetics Global in a research report on Thursday, January 22nd. Roth Mkm initiated coverage on Prenetics Global in a research report on Wednesday, February 11th. They set a “buy” rating and a $36.00 price target for the company. Finally, Wall Street Zen cut shares of Prenetics Global from a “buy” rating to a “hold” rating in a research note on Monday, February 16th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $34.00.

Prenetics Global Stock Down 11.7%

Shares of PRE stock opened at $17.05 on Monday. The company has a market capitalization of $286.95 million, a price-to-earnings ratio of -4.24 and a beta of 0.35. Prenetics Global has a 12-month low of $3.09 and a 12-month high of $22.86. The firm has a fifty day moving average of $17.80 and a 200-day moving average of $14.07.

Prenetics Global (NASDAQ:PRE) last announced its earnings results on Wednesday, February 18th. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.22. Prenetics Global had a negative net margin of 61.33% and a negative return on equity of 19.07%. The firm had revenue of $36.60 million for the quarter, compared to the consensus estimate of $36.15 million.

Institutional Trading of Prenetics Global

Several institutional investors and hedge funds have recently added to or reduced their stakes in PRE. Wells Fargo & Company MN acquired a new position in shares of Prenetics Global during the 4th quarter worth about $47,000. JPMorgan Chase & Co. acquired a new position in Prenetics Global during the third quarter worth approximately $65,000. Manatuck Hill Partners LLC bought a new stake in Prenetics Global in the fourth quarter valued at approximately $170,000. T3 Companies LLC bought a new stake in Prenetics Global in the fourth quarter valued at approximately $170,000. Finally, Kingsview Wealth Management LLC acquired a new stake in shares of Prenetics Global in the fourth quarter valued at approximately $172,000. 25.01% of the stock is owned by institutional investors.

Prenetics Global Company Profile

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.